Skip to content

Bioventus BVS Allowance for Doubtful Accounts Receivable (Current)

Allowance for Doubtful Accounts Receivable (Current) at other companies

Enovis logo
EnovisENOV
$30.22M+12.6%
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
$23.7M-10.9%
IAR
Integra LifeSciencesIART
$7.41M+14.3%
Axogen logo
AxogenAXGN
$822K-14.4%
Medtronic logo
MedtronicMDT
Globus Medical logo
Globus MedicalGMED

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's allowance for doubtful accounts receivable (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's allowance for doubtful accounts receivable (current)?
Bioventus (BVS) reported allowance for doubtful accounts receivable (current) of $3.06M in Q1 2026.
How has Bioventus's allowance for doubtful accounts receivable (current) changed year-over-year?
Bioventus's allowance for doubtful accounts receivable (current) increased by 8.0% year-over-year, from $2.83M to $3.06M.
What is the long-term trend for Bioventus's allowance for doubtful accounts receivable (current)?
Over 5 years (2020 to 2025), Bioventus's allowance for doubtful accounts receivable (current) has grown at a -6.2% compound annual growth rate (CAGR), from $3.99M to $2.9M.
What does allowance for doubtful accounts receivable (current) mean?
This is the valuation allowance for current receivables that are considered uncollectible due to disputes, bankruptcy, or other non-payment issues. It serves as a buffer against potential losses from customer defaults. It is a critical indicator of the health of the company's accounts receivable portfolio.